Nephrocare Health Services Limited

As of June 30, 2026, Nephrocare Health Services Limited carries a market capitalization of 67.97B, placing it among publicly traded companies globally. Its enterprise value stands at 67.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nephrocare Health Services Limited's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Nephrocare Health Services Limited has 100.34M shares outstanding.

As of June 30, 2026, Nephrocare Health Services Limited trades at a trailing price-to-earnings ratio of 78.55.

As of June 30, 2026, Nephrocare Health Services Limited trades at an EV/EBITDA multiple of 28.01 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 45.87 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 67.97B versus a market cap of 67.97B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 2.28M in revenue per employee across its workforce of 4,613.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Nephrocare Health Services Limited recorded 248.75M in income tax expense. That works out to an effective tax rate of 22.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.10B, leaving 851.08M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 23, 2026. The 50-day moving average sits at 680.70, while the 200-day moving average is 614.40.

Over the twelve months ended June 30, 2026, Nephrocare Health Services Limited generated 10.51B in revenue and converted that into 851.08M in net income, yielding earnings per share of 8.47. EBITDA reached 2.43B, while operating income came in at 1.48B.

Over the twelve months ended June 30, 2026, Nephrocare Health Services Limited posted a gross margin of 58.50, reflecting its pricing power and cost economics. The operating margin of 14.10 and net profit margin of 8.10 provide insight into operational efficiency.